invasion within the gastric wall, in 752 patients with gastric cancer treated with curative resection at the Department of Gastroenterological Surgery, Osaka University Hospital. The peritoneum was the most frequent site of recurrence in patients with gastric cancer who received curative resection (34.3%). Furthermore, the frequency increased with increased depth of invasion of the gastric wall (subserosal invasion, 34.9%; serosal invasion, 46.7%; and invasion of adjacent organs, 60.0%).
Introduction
The prognosis of advanced gastric cancer, especially that of serosa-invading tumors, remains poor even after curative operation, and in these patients, peritoneal dissemination, mainly caused by the seeding of free cancer cells from the primary gastric cancer, is the most common type of spread [1, 2] . Table 1 shows the frequency and type of recurrence, according to the depth of tumor Signifi cance of micrometastasis in lymph node, blood, and bone marrow specimens of patients with gastric cancer Occult tumor cells in gastric cancer, missed by conventional pathological examination and detected by PCR or immunohistochemistry, have been studied for more than 10 years. Micrometastasis in lymph nodes obtained from gastric cancer surgery has been frequently assessed, especially with immunohistochemical analysis. However, the clinical impact of micrometastasis in dissected lymph nodes in gastric cancer has been controversial [18] [19] [20] [21] . Although the detection of cancer cells in peripheral blood and bone marrow specimens has also been reported in gastric cancer, the clinical impact on patient prognosis and disease recurrence has not been clarifi ed [22] [23] [24] .
Molecular approach to the detection of free cancer cells in peritoneal lavage
The most common method for the detection of cancer cells in peritoneal lavage is the amplifi cation of messenger RNA (mRNA) that is specifi c to epithelial cells or cancer cells, by RT-PCR. In this method, peritoneal lavage specimens are centrifuged and the cell pellets are subjected to RNA isolation. The RT-PCR technique has been widely used for the amplifi cation and detection of target RNA molecules. Table 2 lists studies of the genetic diagnosis of peritoneal lavage in patients with gastric cancer, together with the molecular markers used for the detection of free cancer cells in the peritoneal cavity. Carcinoembryonic antigen (CEA) mRNA has been commonly used for RT-PCR-based molecular detection. However, some gastric cancer tumors do not express CEA mRNA and additional markers such as cytokeratins were also used in some studies [10, 11] . Other markers, such as matrix metalloproteinase-7 [47] IHC & RT-PCR Trypsinogen 1998 Kodera [16] RT-PCR CEA Peritoneal recurrence; survival 2000 Mori [25] TRAP assay Telomerase 2000 Nakanishi [13] Q-RT-PCR CEA 2001 Yonemura [14] RT-PCR MMP-7 Peritoneal recurrence; survival 2001 Yonemura [48] RT [28] RT-PCR+DNA array Q-RT-PCR, Quantitative RT-PCR (MMP-7) and telomerase activity were also used, because these molecules play an important role in cancer cell invasion and survival [14, 25] . Other candidate molecular markers have also been identifi ed, such as dopa decarboxylase and L-3 phosphoserine phosphatase, which are overexpressed in gastric cancer cell lines and silenced in normal gastric mucosa, as demonstrated by microarray analysis [26, 27] . Recently, Mori et al. [28] developed a novel molecular method of a miniarray-based multiple-marker assay for peritoneal lavage micrometastasis, which combines RT-PCR and miniarray detection. Over the past 5 years, a quantitative PCR system with continuous fl uorescence monitoring of PCR products has been introduced to allow accurate quantifi cation of the initial template copy number of target molecules [10, 17] . The LightCycler (Roche Diagnostics, Basel, Switzerland) has been widely used worldwide as a rapid, quantitative thermal cycler. In this system, the fl uorescence produced from doublestrand DNA-binding fl uorescence dye is monitored once per cycle (real time) and the standard's amplifi cation curve is identifi ed with control specimens, which enables the operator to quantify the relative number of cancer cells in the reaction tube. The thermal cycler also uses small capillary tubes, which allows a rapid change in reaction temperatures. With these advantages, the system has enhanced the reliability and rapidity of genetic diagnosis with the PCR system ( Fig. 1 ), which encouraged us to introduce it for clinical use. Table 2 provides a review of studies that examined the clinical signifi cance of the molecular diagnosis of peritoneal lavage in gastric cancer. Most of these reports emphasized the clinical signifi cance of molecular diagnosis using peritoneal lavage fl uid in gastric cancer, especially for predicting peritoneal recurrence and survival time.
Clinical signifi cance of molecular diagnosis of peritoneal spread
In the studies listed in Table 2 , peritoneal molecular diagnosis at surgery was closely correlated with clinicopathological parameters. Table 3 shows the correlation between the results of RT-PCR using peritoneal lavage collected at laparotomy and various clinical parameters at our institute. Genetic diagnosis was correlated with lymph node metastasis, depth of invasion of the gastric wall, stage classifi cation, P factor (peritoneal metastasis) and CY factor (peritoneal lavage cytology). Figure 2 shows the overall survival and peritoneal recurrencefree survival curves of patients with serosa-invading gastric tumors, based on the results of peritoneal lavage diagnosis using cytology and RT-PCR at surgery. The prognosis of patients with positive cytology in the peritoneal lavage was very poor, and most patients died within 1 year after surgery. Among the patients with negative cytology, those with a positive genetic diagno- The intensity of fl uorescence produced from PCR products was calculated at each thermal cycle and a standard curve was constructed using serial dilutions of control cancer cell lines sis had a signifi cantly poorer prognosis than those with negative genetic results. Follow-up analysis showed that more than half of the patients with positive PCR and CY0 developed peritoneal recurrence after surgery, while almost all patients with negative PCR and CY0 had no peritoneal recurrence after surgery. Based on these results, we conclude that molecular diagnosis using peritoneal lavage fl uid is useful to predict peritoneal recurrence for patients with serosal invasion of gastric tumors.
Immunocytochemical analysis using peritoneal lavage specimens
In addition to the above PCR-based methods, some groups have used immunocytochemical analysis to detect cancer cells in peritoneal lavage [29, 30] . Nekarda et al. [31] reported the frequent detection of free peritoneal tumor cells by immunocytochemistry with the monoclonal antibody Ber-EP4. According to their report, 34% of patients with serosa-invaded tumors showed the presence of free cancer cells by immunocytochemistry. Furthermore, the free cancer cells detected by immunocytochemistry were shown to be an independent prognostic factor in gastric cancer.
Tumor markers in peritoneal lavage specimens
Tumor markers, including the CEA level, were examined in peritoneal lavage fl uid and the associations with prognosis and peritoneal recurrence were assessed [32, 33] . Yamamoto et al. [34] evaluated the tumor markers CEA, carbohydrate antigen (CA) 125, and CA19-9 in peritoneal lavage fl uid, using a chemiluminescent enzyme immunoassay. They concluded that CEA was the most reliable tumor marker in peritoneal lavage fl uid for peritoneal dissemination in gastric cancer. However, Wang et al. [35] compared the results of an RT-PCR assay with CEA and a combination of cytology and peritoneal CEA assay (pCEA)and they concluded that the RT-PCR assay with CEA was more sensitive than the combination of cytology and pCEA.
Novel molecular techniques for detection of micrometastasis
New simple and rapid molecular techniques for the detection of target mRNAs have been developed in recent years. One of the promising techniques is the reverse transcription loop-mediated isothermal amplification (RT-LAMP) reaction, a novel technique designed to detect mRNA expression of targeted sequences with high sensitivity and rapidity. Horibe and coworkers [36] reported the usefulness of the method with cytokeratin-19 as a marker for the detection of micrometastasis in dissected lymph nodes of gastric cancer. The method does not need the RNA extraction phase and uses homogenized crude specimens, which can improve the rapidity, with the method taking 1 h or less [36] .
We have also developed a novel molecular diagnostic technique with another RNA amplifi cation system called transcription-reverse transcription concerted reaction (TRC). The method amplifi es the target mRNAs directly without the reverse-transcription step in a one-tube reaction, by isothermal amplifi cation with RNA polymerase. The TRC method is superior to the RT-PCR method in rapidity and simplicity (Fig. 3) [37] . We applied the method with CEA as a marker for the detection of free cancer cells in peritoneal washes. The sensitivity and quantifi cation of the TRC reaction for the detection of occult cancer cells in peritoneal washes were comparable to those of the conventional quantitative RT-PCR with the LightCycler [37] . It is anticipated that these post-PCR diagnostic systems will contribute to the clinical application of genetic diagnosis in the near future.
Limitation of the molecular approach for the detection of micrometastasis
One major issue with the molecular approach to the detection of micrometastasis relates to the problem of false-positive diagnosis. Several reports have pointed out the limitation of the RT-PCR technique because of the high false-positive rates [38] . The false-positive results could be attributed to one of the following two factors: it could be that these positive results are due to the illegitimate expression of marker genes in noncan- probe. The progress of the reaction is monitored by measuring the fl uorescence intensity from RNA products The TRC method consists of three steps: (1) trimming, (2) amplifi cation, and (3) detection. Black dots, reverse transcriptase; gray dots, T7 RNA polymerase cerous cells [39, 40] . The second reason for the falsepositive result arises from the inherent properties of molecular diagnostic techniques; i.e., their high sensitivity and ability to detect marker gene(s) in only a few cancer cells that are otherwise clinically insignifi cant, as they are unlikely to form metastases.
Clinical application of molecular diagnostic techniques
Based on the results that showed the predictive value of molecular diagnosis of metastatic spread into the peritoneum, we introduced molecular diagnosis as a routine clinical tool in gastric cancer [41] . Preoperative peritoneal lavage diagnosis is applied at the time of the staging laparoscopy for advanced gastric cancer with serosa-invading tumors. Patients with CY0 who are RT-PCR-positive receive short-term intraperitoneal chemotherapy through a 14-Fr gastric tube inserted into the abdominal cavity at the time of staging laparoscopy [41] . Molecular diagnostic techniques using peritoneal lavage are applied at the time of surgical resection, which is usually conducted after chemotherapy. The prognosis of patients who showed a change in the result of genetic diagnosis from positive to negative was signifi cantly improved compared to those who remained positive after chemotherapy. This result suggests that genetic diagnosis can be useful for predicting the effect of chemotherapy, in addition to the prediction of a high risk of peritoneal recurrence. Yamamoto et al. [42] introduced the procedure of extensive intraoperative peritoneal lavage (EIPL) and a rapid RT-PCR detection system with CEA and cytokeratin (CK)-20. The RT-PCR of EIPL fl uid performed after surgery frequently detected positive results, especially in patients with lymph node metastasis, leading to the speculation that lymph node dissection could have opened the lymphatic channels, resulting in the spread of viable cancer cells into the peritoneal cavity. Yamamoto et al. [42] concluded that one advantage of EIPL was that it reduced the number of cancer cells analyzed by quantitative RT-PCR and might thus improve prognosis. Although further investigations will be needed to assess the usefulness of EIPL for gastric cancer with lymph node metastasis, the introduction of quantitative molecular diagnosis may possibly improve the management of cancer treatment.
Future perspectives of peritoneal lavage diagnosis by genetic techniques
In advanced gastric cancer, the peritoneum is the most common site of metastasis and recurrence. Furthermore, it is often diffi cult to diagnose peritoneal dissemination at an early stage and to treat such patients. For these reasons, the use of molecular diagnosis with peritoneal lavage fl uid has been investigated extensively during the past 10 years, especially in patients with gastric cancer ( Table 2) . As we have shown here, there is compelling evidence for the utility of genetic techniques in the diagnosis of metastasis and spread in the peritoneum. Using genetic techniques, we can select patients at high risk as well as those at low risk for peritoneal recurrence. For high-risk patients, more aggressive chemotherapy such as intraperitoneal chemotherapy or chemohyperthermia may be justifi able to prevent peritoneal recurrence [43] [44] [45] . Recent clinical trials from Japan have reported the signifi cance of chemotherapy with S-1, a novel oral fl uoropyrimidine derivative, after curative surgery [46] . Based on the results of these trials, the oral administration of S-1 for 1 year has been recommended for patients with stage II and stage III gastric cancer [46] . However, the adverse effects and the high medical costs of S-1 chemotherapy make this treatment not suitable for all patients. In fact, one-third of patients who were scheduled for S-1 chemotherapy could not complete the entire course of such therapy [46] . Therefore, patients identifi ed as low-risk, based on genetic diagnosis, could be excluded from such chemotherapy after curative resection.
In April 2006, the Japanese Government included the genetic diagnosis of body fl uids in the public health insurance program for patients with solid tumors. This step has facilitated the introduction into clinical practice of genetic diagnostic techniques for peritoneal lavage from patients with gastric cancer. However, at present, genetic diagnosis can be performed only at University hospitals and large cancer centers. To make genetic diagnosis a routine service, methods of molecular diagnosis, which now show many differences among institutions, will need to be standardized, and simple diagnostic devices and commercially based kits should be available for laboratory technicians. Furthermore effective treatments for patients with a positive peritoneal molecular diagnosis need to be developed by multiinstitutional trials.
